Dopamine Metabolism in Human Brain: Effects of Monoamine Oxidase Inhibition in vitro by (—)Deprenyl and (+) and (—)Tranylcypromine

1980 ◽  
pp. 173-178 ◽  
Author(s):  
G. P. Reynolds ◽  
P. Riederer ◽  
W.-D. Rausch
Keyword(s):  
Monoamine Oxidase ◽  
Human Brain ◽  
Dopamine Metabolism ◽  
Monoamine Oxidase Inhibition ◽  
Oxidase Inhibition

Monoamine Oxidase Inhibition by Ethanol in vitro

Nature ◽  
1962 ◽  
Vol 196 (4854) ◽  
pp. 575-576 ◽  
Author(s):  
LAURENCE S. MAYNARD ◽  
VICTOR J. SCHENKER
Keyword(s):  
Monoamine Oxidase ◽  
Monoamine Oxidase Inhibition ◽  
Oxidase Inhibition

scholarly journals Electrophysiological effects of monoamine oxidase inhibition on rat midbrain dopaminergic neurones: an in vitro study

1996 ◽  
Vol 117 (3) ◽  
pp. 528-532 ◽  
Author(s):  
Nicola B. Mercuri ◽  
Antonello Bonci ◽  
Antonio Siniscalchi ◽  
Alessandro Stefani ◽  
Paolo Calabresi ◽  
...  
Keyword(s):  
Monoamine Oxidase ◽  
In Vitro Study ◽  
Vitro Study ◽  
Monoamine Oxidase Inhibition ◽  
Oxidase Inhibition ◽  
Electrophysiological Effects

Tyramine kinetics and pressor sensitivity during monoamine oxidase inhibition by selegiline

1989 ◽  
Vol 46 (5) ◽  
pp. 528-536 ◽  
Author(s):  
Rainer Schulz ◽  
Karl-Heinz Antonin ◽  
Edgar Hoffmann ◽  
Maria Jedrychowski ◽  
Eric Nilsson ◽  
...  
Keyword(s):  
Monoamine Oxidase ◽  
Monoamine Oxidase Inhibition ◽  
Oxidase Inhibition

scholarly journals Glycaemic control by monoamine oxidase inhibition in a patient with type 1 diabetes

2016 ◽  
Vol 14 (2) ◽  
pp. 163-165 ◽  
Author(s):  
Hamlin Emory ◽  
Neptune Mizrahi
Keyword(s):  
Type 1 Diabetes ◽  
Glycaemic Control ◽  
Monoamine Oxidase ◽  
Monoamine Oxidase Inhibitor ◽  
Combined Treatment ◽  
Insulin Regimen ◽  
Imaging Data ◽  
Monoamine Oxidase Inhibition ◽  
Oxidase Inhibition

We present clinical, electroencephalographic and low-resolution electromagnetic tomography data that support combined treatment with insulin and a monoamine oxidase inhibitor in a patient with type 1 diabetes. We suggest that brain imaging data can identify a subgroup of patients who are likely to benefit from an insulin regimen and monoamine oxidase inhibition to improve glycaemic control, cardiovascular function, normalize the circadian rhythm and restore perception of glycaemic awareness.

Sign in / Sign up

Export Citation Format

Share Document